Fundraising FoxBrace Pharma — Full Portfolio
15 tracked investments · listed companies and verified rows first
miRagen Therapeutics is a biopharmaceutical company developing monoclonal antibodies and other engineered protein therapeutics targeting specific receptors (IGF-1R, FcRn, and TSHR) for autoimmune and rare diseases including thyroid eye disease, Graves' disease, and various autoimmune conditions.
BiotechBoulder, US
William S. Marshall(Executive Officer, Director)Jason A. Leverone(Executive Officer)inDavid Rodman(Executive Officer)Stephen Mahoney(President, Chief Executive Officer and Director)Thomas Beetham(Chief Operating Officer)inRadhika Tripuraneni(Chief Medical Officer)in
Co-investorsBroadview VenturesMC Healthcare VenturesRidgeback CapitalAtlas VentureBoulder VenturesHeartland+1 more
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
BoardROBERT ADELMAN(Director)
Co-investorsage1Agent CapitalAliment CapitalF-Prime CapitalOCV PartnersOUP (Osage University Partners)+6 more
Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.
BiotechHealthtechVancouver, US
ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)inSURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in
Co-investorsCTI Life Sciences Fund L.P.HBM Healthcare InvestmentsLumira VenturesNextech InvestWUTIF CapitalAmplitude Venture Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalAvestria VenturesCanaan PartnersGV (Google Ventures)HBM Healthcare InvestmentsHBM Partners+6 more
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)inMark E. Davis(Director)Troy Wilson(Executive Officer, Director)in
BoardTodd Brady(Director)Michael Martin PhD.(Director)
Co-investorsAvoro Capital AdvisorsF-Prime CapitalFrazier Life SciencesMoore Venture Partners
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsAdvent Life SciencesAisling CapitalAMR Action FundAstellas Venture Management LLCSofinnova PartnersSunstone Capital+3 more
Baltimore-based immunology company focused on treatments for cancer and autoimmune disorders; raised an $11.5 million Series C led by First In Ventures.
BiotechBaltimore, US
David S. Block(Executive Officer, Director)Elizabeth C. Block(Executive Officer)Raymond Shinazi(Director)Joseph Klein(Director)Mark Lerner(Director)
BoardCharles Polsky(Director)
Co-investorsFirst In Ventures
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)in
BoardJean-Francois Formela(Director)inAlan Crane(Director)inMarian Nakada(Director)inBrian Gallagher(Director)in
Co-investorsage1Sanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
Reviral operates an affiliate review site that ranks and reviews online casinos not registered with the UK's GamStop self-exclusion scheme, comparing licences, bonuses, wagering terms, payout speeds, and payment methods.
ConsumerMedia & Entertainment
Co-investorsAndera PartnersNew Leaf Venture PartnersOrbiMedWellcome Trust
BiotechNew York, US
Michael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)inJane Henderson(Executive Officer)inStefan Larson(Director)Patrick Machado(Director)
Co-investorsF-Prime CapitalFACIT (Fight Against Cancer Innovation Trust)Foothill VenturesVenture OntarioOrbiMedPoint72+1 more
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings.
BiotechHealthtechMedical Devices
Co-investorsRunway Growth CapitalMVM Life Science Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
AvrobioGeNO LLCTyrogenex
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.